What to Look for When Pfizer Inc. Reports Earnings

Pfizer's upcoming earnings call is likely to be followed by a wave of commotion. Here are some key factors you can listen in for to draw your own opinion.

Jan 22, 2014 at 6:30PM

Pfizer's (NYSE:PFE) earnings call is coming up on Tuesday, January 28, just after the market opens. Losses from generic competition, an ongoing organizational overhaul, and string of recent downgrades will make this one of the most listened to calls of the season. With this much attention, there is likely to be a great deal of noise immediately following the call, but here are a a few critical points to help you focus on the essentials.

Unloading generics
Halfway through last year, Pfizer discussed the separation of its commercial operations into three distinct units. Two units for patent protected brands and one for generics. According to Reuters, Valeant Pharmaceuticals (NYSE: VRX), Mylan Inc (NASDAQ:MYL), and Actavis (NYSE: ACT), are all interested, but there's a small problem -- they probably can't afford it.

VRX Free Cash Flow (TTM) Chart

VRX Free Cash Flow (TTM) data by YCharts

Pfizer's generics operations are contained within its Established Products and Emerging Markets reporting segment. It hauled in about $14.5 billion during the first nine months of 2013. The odds of any one of the above companies raising enough cash to make an outright purchase are slim. Also, the sale of smaller pieces to interested parties would probably incur enough taxes to erode the sales' profitability.

The company could avoid the tax charges if it were to spin-off the generics unit, then allow it to merge with a smaller company that later assumes full control of the new entity. Valeant, for one, appears willing to do such a deal.

When Pfizer last reported earnings the company was still focused on setting up the new organization model of two innovative businesses and one established business segment. Management doesn't appear to be in a hurry here, but listen in for more talk of reorganization. There may at least be hints of a spin off, which would allow the company to direct more of its resources toward the development of new therapies.

Xeljanz
Generics aside, Pfizer has been plagued with slow launches of products expected to become blockbusters. During Q3 2013, the company recorded Xeljanz sales of just $35 million. The oral treatment for rheumatoid arthritis is facing intense competition from AbbVie's top seller Humira, and Amgen's Enbrel. Sure the competition is entrenched, but Xeljanz is a pill, versus its competitors' injectables. Apparently, this differentiating factor has not been a significant tailwind for sales.

A label expansion to psoriasis may have to wait. During an ongoing phase 3 trial pitting Enbrel against Xeljanz, Pfizer's drug was similarly effective at a 10 mg dose. Unfortunately, it is unlikely to win an approval at that dosage due to safety concerns. If the lower dosage, which may be less effective than Enbrel, wins approval it is hard to imagine dermatologists falling in love with it.

There are a slew of ongoing clinical trials intended to expand Xeljanz's label, but it seems for the next couple years, its growth will depend on adoption among rheumatoid arthritis patients. The company has increased its marketing efforts, I'll be listening in closely to see if sales of this potential blockbuster are accelerating.

Eliquis
Similar to Xeljanz, this is another potential blockbuster that hit the ground crawling. Along with partners Bristol-Myers Squibb (NYSE: BMY), Pfizer launched this anticoagulant late in 2012, and it ran face-first into existing competition. The drug should be able to compete on its lower incidence of bleeding episodes, but few seem to have noticed.

Pfizer began a direct-to-consumer television ad campaign late in September 2013. If Pfizer can differentiate Eliquis from the competition, it would go a long way toward returning the company to growth. I'll be listening closely for signs that the campaign is working.

Emerging markets and oncology
Of Pfizer's three reporting segments, all three lost some ground during the first nine months of 2013, compared to the same period a year previous. During Q3 2013, the Established Products and Emerging Markets segment fell a little less than 1%, and the Specialty Care and Oncology segment actually grew just a bit compared to the same period a year previous.

Strong growth in oncology and emerging markets aren't likely to return the company to topline growth on their own, but they just might be enough to stop the losses. On the other hand, if there is any sign of these divisions losing steam, things could get ugly.

Stay cool
With this handful of points to stay focused on, you should be prepared to make your own assessment of the earnings release. If you're listening to the call, you'll also have specifics to listen in for. If you're holding shares of Pfizer, its competition, or a potential suitor of the generics business, staying informed will put you a step ahead. The market has a tendency to overreact first, then ask questions later. Stay sharp, and you might be able to spot an opportunity.

Pfizer's dividend is still going strong, but is this a Dow stock investors need to own?
If you're looking for some long-term investing ideas, you're invited to check out The Motley Fool's brand-new special report, "The 3 Dow Stocks Dividend Investors Need." It's absolutely free, so simply click here now and get your copy today.

Cory Renauer has no position in any stocks mentioned. The Motley Fool recommends Valeant Pharmaceuticals. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

1 Key Step to Get Rich

Our mission at The Motley Fool is to help the world invest better. Whether that’s helping people overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we can help.

Feb 1, 2016 at 4:54PM

To be perfectly clear, this is not a get-rich action that my Foolish colleagues and I came up with. But we wouldn't argue with the approach.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich" rated The Motley Fool as the #1 place online to get smarter about investing.

"The Motley Fool aims to build a strong investment community, which it does by providing a variety of resources: the website, books, a newspaper column, a radio [show], and [newsletters]," wrote (the clearly insightful and talented) money reporter Kathleen Elkins. "This site has something for every type of investor, from basic lessons for beginners to investing commentary on mutual funds, stock sectors, and value for the more advanced."

Our mission at The Motley Fool is to help the world invest better, so it's nice to receive that kind of recognition. It lets us know we're doing our job.

Whether that's helping the entirely uninitiated overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we want to provide our readers with a boost to the next step on their journey to financial independence.

Articles and beyond

As Business Insider wrote, there are a number of resources available from the Fool for investors of all levels and styles.

In addition to the dozens of free articles we publish every day on our website, I want to highlight two must-see spots in your tour of fool.com.

For the beginning investor

Investing can seem like a Big Deal to those who have yet to buy their first stock. Many investment professionals try to infuse the conversation with jargon in order to deter individual investors from tackling it on their own (and to justify their often sky-high fees).

But the individual investor can beat the market. The real secret to investing is that it doesn't take tons of money, endless hours, or super-secret formulas that only experts possess.

That's why we created a best-selling guide that walks investors-to-be through everything they need to know to get started. And because we're so dedicated to our mission, we've made that available for free.

If you're just starting out (or want to help out someone who is), go to www.fool.com/beginners, drop in your email address, and you'll be able to instantly access the quick-read guide ... for free.

For the listener

Whether it's on the stationary exercise bike or during my daily commute, I spend a lot of time going nowhere. But I've found a way to make that time benefit me.

The Motley Fool offers five podcasts that I refer to as "binge-worthy financial information."

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. It's also featured on several dozen radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable ... and I don't say that simply because the hosts all sit within a Nerf-gun shot of my desk. Rule Breaker Investing and Answers contain timeless advice, so you might want to go back to the beginning with those. The other three take their cues from the market, so you'll want to listen to the most recent first. All are available at www.fool.com/podcasts.

But wait, there's more

The book and the podcasts – both free ... both awesome – also come with an ongoing benefit. If you download the book, or if you enter your email address in the magical box at the podcasts page, you'll get ongoing market coverage sent straight to your inbox.

Investor Insights is valuable and enjoyable coverage of everything from macroeconomic events to investing strategies to our analyst's travels around the world to find the next big thing. Also free.

Get the book. Listen to a podcast. Sign up for Investor Insights. I'm not saying that any of those things will make you rich ... but Business Insider seems to think so.


Compare Brokers